Jump to content

1Z2MAP1O

Add links
From Wikipedia, the free encyclopedia

1Z2MAP1O
Clinical data
Other names1-(Indolizin-3-yl)-2-(methylamino)propan-1-one; Structure XLX
Drug classMonoamine releasing agent; Serotonin 5-HT1B receptor agonist; Serotonin 5-HT2B receptor antagonist; Entactogen
Identifiers
  • 1-indolizin-3-yl-2-(methylamino)propan-1-one
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC12H14N2O
Molar mass202.257 g·mol−1
3D model (JSmol)
  • CC(C(=O)C1=CC=C2N1C=CC=C2)NC
  • InChI=1S/C12H14N2O/c1-9(13-2)12(15)11-7-6-10-5-3-4-8-14(10)11/h3-9,13H,1-2H3
  • Key:BFSFBVDVCJVAMW-UHFFFAOYSA-N

1Z2MAP1O, also known as 1-(indolizin-3-yl)-2-(methylamino)propan-1-one, is a monoamine releasing agent and serotonin receptor modulator of the indolizine class.[1] It is an analogue of BK-NM-AMT (β-keto-N-methyl-α-methyltryptamine) in which the indole ring has been replaced with an indolizine ring.[1]

1Z2MAP1O has been found to be a serotonin and dopamine releasing agent as well as a weak serotonin 5-HT1B receptor agonist and serotonin 5-HT2B receptor antagonist.[1] Conversely, its activity as a norepinephrine releasing agent was not reported, and it was inactive at the remaining sites of the 47 screened targets.[1] The drug's EC50Tooltip half-maximal effective concentration values for induction of monoamine release were 109 nM for serotonin and 227 nM for dopamine in Chinese hamster ovary (CHO) cells expressing the human monoamine transporters (MATs).[1] The dopamine/serotonin ratio was 0.48.[1] Its EC50 at the serotonin 5-HT1B receptor was 1,130 nM, whereas its IC50Tooltip half-maximal inhibitory concentration values were 2,140 nM at the serotonin 5-HT2B receptor, 2,410 nM at the dopamine transporter (DAT), and 5,690 nM at the norepinephrine transporter (NET).[1] 1Z2MAP1O's inhibition of the serotonin transporter (SERT) was not reported.[1]

1Z2MAP1O was patented by Matthew Baggott of Tactogen in 2023.[1]

See also

[edit]

References

[edit]
  1. ^ a b c d e f g h i WO application 2023081306A1, Baggott MJ, "Indolizine compounds for the treatment of mental disorders or mental enhancement", published 11 May 2023, assigned to Tactogen 


Stub icon

This psychoactive drug-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=1Z2MAP1O&oldid=1279442580"